The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
3M acquired Acolyte Biomedica,
manufacturer of the BacLite Rapid system, an automated microbial detection
platform that aids in the rapid detection, diagnosis, and treatment of
infectious diseases. In January 2006,
Acolyte launched a rapid culture-based MRSA test, BacLite Rapid, which can
detect the presence or absence of MRSA
direct from clinical samples in less than five hours.
BD
Biosciences and Roche formed a collaboration to identify and develop intracellular phosphorylation site antibodies that
will improve their understanding of the pathways that carry information inside
of cells and why these pathways sometimes malfunction to cause disease. The goal is the discovery of new drugs and
biological markers for life-threatening conditions.
Beckman
Coulter exercised its option to continue to license
patent rights relating to the use of High Mobility Group Box 1 (HMGB1) technology from Critical Therapeutics. HMGB1 is an emerging marker for acute and
chronic diseases resulting in multi-organ failure, including sepsis and septic
shock, chronic inflammatory diseases, and rheumatoid arthritis.
Cytyc
Corporation is buying Adeza Biomedical Corporation for $452 million. Adeza's key product, FullTerm, The Fetal
Fibronectin Test, is used to identify women at risk of preterm birth.
Gynecor introduced TruTest that uses a gentle brushing technique to collect
a uterine biopsy from the patient in
the physicians' office. The specimen is
then returned to Gynecor where it is tested by tissue histology, cytology and HPV
genotyping.
Idaho
Technology launched its Razor system a POC device capable
of performing DNA-based pathogen
detection in 30 minutes. It utilizes
a real-time PCR plastic freeze-dried reagent format where samples are loaded
with syringes into cartridges.
Inverness
Medical completed its third acquisition in a month. The
acquisitions include: First Check
Diagnostics’ OTC products for drugs, alcohol, cholesterol and FOB; Promesan
SRL, an Italian distributor of medical diagnostics products; and Canadian
distributor Med-Ox Chemicals.
Quest
Diagnostics acquired HemoCue, specializing from the private equity firm EQT II B.V. in a
cash transaction valued at approximately $420 million. The acquisition will
allow Quest Diagnostics to enter the growing near patient testing market
Quidel
and Cholestech joined forces to offer the Accu-Tame
program to dermatologists as a tool in prescribing isotretinoin, an acne treatment that carries a significant risk of
birth defects if taken during pregnancy. The prescribing label requires that they test
patients for pregnancy and lipids and liver enzymes.
SpheroSense
Technologies is developing a disposable, continuous-monitoring
device for the early detection of sepsis.
The biosensor can detect circulating small
molecules, drugs, proteins, viruses, DNA and RNA
![[Page Banner Image]](images/hprods.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
